Kornimate/medical-research-clean huggingface dataset:
pediatric kidney transplantation, ureteroneocystostomy techniques

Conditions: Kidney Transplant; Complications; Kidney Transplant Infection; Kidney Transplant Failure and Rejection

Summary: in this study the researchers want to retrospectively compare non-refluxing ureteroneocystostomy (unc techniques to reflux unc techniques in paediatric kidney recipients with regard to urinary tract infections and uteral obstruction.

multi-center retrospective study and survey on clinical practice among different urologists. the researchers will retrospectively study data on patients that received their kidney graft between 1994-2018 in either radboudumc or uw health university hospital in winsconsin. additionally, all urologist currently employed at those hospitals will be asked to fill in a survey on preferences in unc techniques and suture material.

Eligibility criteria:
inclusion criteria: * received kidney graft in the participating centres at an age \<19 * received kidney graft between 1994-2018 * follow-up data of at least 1 year exclusion criteria: - loss of follow up \< 1 year

Keywords: kidney transplantation pediatrics
effect of nelutri™ on musculoskeletal biomarkers in relative sarcopenia adults

Conditions: Muscular Sarcoidosis

Summary: the investigators conduct a randomized, double-blind, placebo-controlled study to investigate the effects of nelutri™on muscle strength, muscle mass, and muscle function in healthy adults for 12 weeks.

a previous study has indicated that nelutri™ may increase muscle mass and strength. therefore, the investigators conduct a randomized, double-blind, placebo-controlled study to investigate the effects of nelutri™on muscle strength, muscle mass, and muscle function in healthy adults; the safety of the compound are also evaluate. the investigators examine the peak torque/body weight at 60°/s knee extension, handgrip strength, skeletal muscle mass, physical performance, and metabolic parameters at baseline, as well as after 6 and 12 weeks of intervention. eighty adults were administered either 2,000 mg of nelutri™ or a placebo each day for 12 weeks;

Eligibility criteria:
inclusion criteria: * \<110% of the standard lean body mass as measured using the body composition analyzer * body-mass index (bmi) ranging from 18.5 to 30.0 kg/m2 * those who have an average protein intake of 60 g or more/day. exclusion criteria: * abnormal liver or renal function (i.e., serum aminotransferase activity \> 60 iu/l and serum creatinine concentrations \> 1.2 mg/dl) * diabetes (diagnosed clinically or fasting glucose level \> 126 mg/dl) * history of fracture during the previous year * uncontrolled hypertension * history of serious cardiac disease such as angina or myocardial infarction * history of gastrectomy * history of medication for psychiatric disease * administration of oriental medicine including herbs within the past 4 weeks * evidence of relatively high skeletal mass (more than 110% of the standard lean body mass as measured using the body composition analyzer
effect of rosiglitazone in nondiabetic patients with the metabolic syndrome

Conditions: Metabolic Syndrome; Insulin Resistance

Summary: the metabolic syndrome is a collection of health risks that includes obesity, high blood pressure, high triglycerides, high blood sugar, low good cholesterol, and resistance to insulin. the purpose of this study is to find out if the medication, rosiglitazone, influences levels of fat cell proteins and alters insulin resistance in nondiabetic persons with the metabolic syndrome. this is an early step to see if a medication, such as rosiglitazone, will be beneficial in people who have the metabolic syndrome.


Eligibility criteria:
inclusion criteria: * nondiabetic subjects with an ncep/atp iii diagnosis of the metabolic syndrome exclusion criteria: * statin medications, liver disease, cardiovascular disease, heart failure, diabetes, chronic kidney disease,
4-valent hpv vaccine to treat recurrent respiratory papillomatosis in children

Conditions: Recurrent Respiratory Papillomatosis

Summary: recurrent respiratory papillomatosis in children caused by hpv 6,11 can be a life threatening condition resulting in surgical interventions. the maturing and disintegrating papillomas are the sources for the subsequent hpv relapses and immunization might slow down or even prevent this ongoing process. after an initial immunological and ear-nose-throat (ent) assessment children with at least 3 relapses in their patient history will be vaccinated with 4-valent hpv vaccine according to the following schedule: 0., 2., 6. months. it will be followed by an immunological and 3 ent examinations to assess response to vaccination.

1. enrollment * ear-nose-throat (ent) examination + oesophagoscopy * immunological assessment * assessment of selected humoral (antibodies) and * cellular immune response parameters(inf gamma and granzyme b testing) * in vitro and in vivo stimulation of pmbcs with the hpv-4 vaccine 2. immunization with 4-valent hpv vaccine at 0,2,6 months 3. follow up * 1 month after 3rd vaccine dose - immunological assessment (same tests as in the enrollment phase) * 6, 12 and 18 months after the 3rd vaccine dose - ent + oesophagoscopy

Eligibility criteria:
inclusion criteria: * respiratory papillomatosis * at least 3 relapses in patient history * hpv 6 and/or 11 positive papillomas * able to mount neutralizing antibodies exclusion criteria: * other chronic underlying condition * other hpv type * no antibody response

Keywords: recurrent respiratory papillomatosis human papillomavirus vaccine treatment immunology relapse
a study of atezolizumab in combination with bevacizumab versus sunitinib in participants with untreated advanced renal cell carcinoma (rcc)

Conditions: Renal Cell Carcinoma

Summary: this multi-center, randomized, open-label study will evaluate the efficacy and safety of atezolizumab plus bevacizumab versus sunitinib in participants with inoperable, locally advanced, or metastatic rcc who have not received prior systemic active or experimental therapy, either in the adjuvant or metastatic setting.


Eligibility criteria:
inclusion criteria: * definitive diagnosis of unresectable locally advanced or metastatic rcc with clear-cell histology and/or a component of sarcomatoid carcinoma, with no prior treatment in the metastatic setting * evaluable memorial sloan kettering cancer center risk score * measurable disease, as defined by recist v1.1 * karnofsky performance status greater than or equal to 70% * adequate hematologic and end-organ function prior to randomization exclusion criteria: disease-specific exclusions: * radiotherapy for rcc within 14 days prior to treatment * active central nervous system disease * uncontrolled pleural effusion, pericardial effusion, or ascites * uncontrolled hypercalcemia * any other malignancies within 5 years except for low-risk prostate cancer or those with negligible risk of metastasis or death general medical exclusions: * life expectancy less than 12 weeks * participation in another experimental drug study within 4 weeks prior to treatment * pregnant or lactating women * known hypersensitivity to any component of atezolizumab or other study medication * history of autoimmune disease except controlled, treated hypothyroidism or type i diabetes mellitus * history of idiopathic pulmonary fibrosis, organizing pneumonia, drug-induced pneumonitis, or idiopathic pneumonitis * positive human immunodeficiency virus test * active or chronic hepatitis b or c * severe infections within 4 weeks prior to treatment * exposure to oral or iv antibiotics within 2 weeks prior to treatment * live attenuated vaccines within 4 weeks prior to treatment (for influenza vaccination participants must agree not to receive live, attenuated influenza vaccine within 4 weeks prior to treatment, during treatment or within 5 months following the last dose) * significant cardiovascular disease * prior allogeneic stem cell or solid organ transplantation exclusion criteria related to medications: * prior treatment with cluster of differentiation 137 agonists, anti-cytotoxic t-lymphocyte associated protein-4, anti-programmed death (pd)-1, or anti-pd-l1 therapeutic antibody or pathway-targeting agents * treatment with immunostimulatory agents for non-malignant conditions within 6 weeks or immunosuppressive agents within 2 weeks prior to treatment bevacizumab- and sunitinib-specific exclusions: * history of hypertensive crisis or hypertensive encephalopathy * baseline electrocardiogram showing corrected qt interval greater than 460 milliseconds
effects of home based exercise therapy in early cirrhosis

Conditions: Cirrhosis

Summary: individuals with cirrhosis have been shown to have a low aerobic capacity. while supervised exercise training has been shown to be an effective intervention to remedy this, there is currently no data on home based exercise interventions in this population. this study will evaluate the effects of a home based exercise program on the aerobic capacity of enrolled early stage liver cirrhosis patients, as well as changes in quality of life, thigh muscle thickness, and thigh muscle oxygen consumption.


Eligibility criteria:
inclusion criteria: - age \>18 and less than or equal to 70 years liver cirrhosis child pugh class a or b if required, primary or secondary variceal prophylaxis in place exclusion criteria: - post-liver transplantation hepatocellular carcinoma beyond transplant criteria active non-hepatocellular carcinoma malignancy significant cardiac disease hemoglobin (\<80 g/l) oxygen saturation at rest \<95% known myopathy chronic renal failure on dialysis physical impairment making it impossible to ride an exercise bike or treadmill orthopedic abnormality preventing exercise training hiv infection patient unwilling to consent to study child pugh class c
comparison of the effectiveness of local ozone injection and dextrose prolotherapy injection in chronic plantar fasciitis

Conditions: Plantar Fascitis

Summary: the aim of our study was to investigate the effect of local ozone injection and dextrose prolotherapy applications on pain and foot functions to compare the efficacy and to evaluate the thickness of the plantar fascia.

in this study, 60 plantar fasciitis patients aged between 18 and 75 years admitted to kırşehir ahi evran university training and research hospital were examined. plantar fasciitis (pf) is a common cause of heel pain associated with gait disorders. is one of the causes and has a significant negative impact on quality of life. the diagnosis is usually made by clinical assessment and no additional investigations are required. treatment with non-steroidal anti-inflammatory drugs, night splints and therapeutic exercises are the first choice extracorporeal shock wave therapy and plasma-rich minimally invasive treatments such as platelet (prp) can also be applied.plantar dextrose prolotherapy, which is another treatment method in fasciitis, improves the ligament structure strengthens and reduces pain.in 2022, chutumstid t et al. conducted a meta-analysis and found that dextrose prolotherapy reduces pain, increases functionality and increases plantar fascia thickness in chronic plantar fasciitis. decreased the risk of complications. seyam omar et al. concluded that ozone therapy can be applied subcutaneously, periarticularly and intraarticularly. it can be preferred due to its low risk and high chance of success. is a treatment method.

Eligibility criteria:
inclusion criteria: * 18-75 years old, both sexes * pain in the plantar medial calcaneal tubercle on palpation for more than 3 months * accepting to participate in the study * heel pain, especially in the first few steps in the morning, increasing with loading during the day * patients with an initial vas assessment of 4 or more on a 10 cm scale exclusion criteria: * hyperthyroidism * glucose6 phosphate dehydrogenase deficiency * ozone allergy * acute metabolic disease comorbidity (acute mi, acute hyperglycaemia, diabetic ketoacidosis, acute cerebrovascular disease etc.) * pregnancy and breastfeeding * malignite * epilepsy * tipl, having a history of type 2 diabetes * history of inflammatory rheumatic disease * history of bleeding disorders * use of anticoagulants other than aspirin * local corticosteroid injection into the plantar fascia within the last 3 months to have a story * eswt treatment of the plantar fascia in the last 3 months * to have received physiotherapy to the foot, ankle area within the last 3 months * history of foot and ankle surgery * active infection at the application site (cellulitis, erysipelas, etc.) * allergy to dextrose * history of peripheral neuropathy * si radiculopathy

Keywords: local ozon therapy rehabilitation dextroz prolotherapy ultrasonography
respiratory disease cohort studies of chinese medicine for pulmonary nodule

Conditions: Pulmonary Nodule; Cohort Study; Traditional Chinese Medicine

Summary: this study is a prospective multicenter cohort study that primarily evaluates the impact of traditional chinese medicine treatment on pulmonary nodules

this study is a multicenter, prospective cohort study that will recruit at least 2244 individuals with chest hrct findings of pulmonary nodules and recommended follow-up by mdt from four research centers. according to whether patients with pulmonary nodules are treated with traditional chinese medicine, they are divided into a traditional chinese medicine cohort and a non-traditional chinese medicine cohort , and are followed up for at least 2 years. the main outcome measures were pulmonary nodule growth (enlargement or new onset) and nodule regression (reduction or disappearance). to evaluate the efficacy of traditional chinese medicine treatment for patients with pulmonary nodules, secondary outcome measures include nodule volume, average nodule density, doubling time of volume, internal and external signs of nodules, anxiety self-assessment scale, depression self-assessment scale and sf-36 scale.

Eligibility criteria:
inclusion criteria: ① patients with pulmonary nodules and recommended for follow-up by mdt; ② voluntarily sign the informed consent form. exclusion criteria: ①patients with metastatic pulmonary nodules; ②patients with benign diseases such as pulmonary lymph nodes, hamartomas, sclerosing alveolar cell tumors, or nodules with obvious benign features such as calcification; ③patients withserious heart, lung, liver and kidney diseases.

Keywords: pulmonary nodule cohort study traditional chinese medicine
nordic cystectomy study iii - transfusion

Conditions: Bladder Cancer; Invasive Bladder Cancer

Summary: around 7200 cases of muscle invasive bladder cancer are diagnosed annually in the nordic countries combined. muscle invasive bladder cancer is an aggressive disease and it is linked with high mortality rates. the golden standard of treatment is radical cystectomy (rc) (the surgical removal of the bladder) and radical removal of lymph nodes in the pelvis. in addition to surgical treatment, and especially in cases where the tumour invades tissues surrounding the bladder or lymph nodes, chemotherapy is recommended. chemotherapy can be administered before or after surgery, in a neoadjuvant (nac) or adjuvant setting (ac). although most patients recover well from surgery, there are significant risks regarding radical cystectomy. the greatest challenges in planning the treatment are making individual risk assessments and prognosis for the treated patients. neoadjuvant chemotherapy is also insufficiently used and it is hard to predict how the tumour responds to chemotherapy. the purpose of this study is to collect prospective clinical data on radical cystectomy -patients in co-operation with other nordic countries: sweden, denmark, iceland and norway. the collected data is used to validate existing prediction tools and discover novel tools for prediction of morbidity related to rc and prediction of oncological outcome after rc. the study is divided into three sub-studies. transfusions during rc and the time of hospitalization after the surgery are associated poorer oncological outcome when compared to those patients who do not need transfusions. the third study focuses on the oncological outcomes in patients receiving blood transfusions. as there are some conflicting reports and the finding is not properly validated, we aim to validate the effect of transfusions on survival after rc. the number of transfusions during rc and the time between surgery and discharge from hospital will be recorded. patient cohort will be divided into patients receiving transfusions and not receiving transfusion. the primary end point is patients receiving transfusion and its effect on cancer specific mortality at 24 months. for patients receiving nac, additional secondary end-point is complete response (pt0n0) rate at rc.


Eligibility criteria:
inclusion criteria: * histologically confirmed urinary bc planned to be treated with rc with or without neoadjuvant chemotherapy. * histologically confirmed urinary bc planned to be treated with palliative cystectomy * signed informed consent * patient age \>18 years exclusion criteria: * rc for other reasons than bc * other forms of surgical treatment of bc than rc (e.g. bladder resection). * patient unwillingness to participate in the study for any reason (i.e. lack of signed consent).
neoadjuvant aromatase inhibitor and pertuzumab/trastuzumab for women with breast cancer

Conditions: Breast Neoplasms

Summary: this is a prospective, single-arm, phase ii study of 32 evaluable patients treated with neoadjuvant aromatase inhibitor and pertuzumab/trastuzumab (neoadapt) without chemotherapy for hormone receptor positive (hr+), \[i.e. estrogen receptor positive (er+) and/or progesterone receptor positive (pr+)\] her2+ localized, non-metastatic stage i - iib breast cancer.


Eligibility criteria:
inclusion criteria: * ability to provide signed, written informed consent * histologically or cytologically confirmed non-metastatic adenocarcinoma of the breast (stage i-ii) * candidate for curative-intent treatment * er+ and/or pr+ and her2-positive (fluorescence in situ hybridization-positive or 3+ by immunohistochemistry staining) * life expectancy greater than 5 years * left ventricular ejection fraction \> 50% at baseline (within 30 days of day 0) * eastern cooperative oncology group performance status ≤2 * absolute neutrophil count \>1000/µl * platelets ≥50,000/µl * hemoglobin \>8.0 g/dl, * creatinine ≤3.0 x upper limit of normal (uln) * bilirubin ≤3.0 x uln * aspartate aminotransferase or alanine aminotransferase \<5.0 x uln * negative serum pregnancy test for women \<12 months after the onset of menopause unless surgically sterilized * agreement by women of childbearing potential and male participants with partners of childbearing potential to use a "highly effective", non-hormonal form of contraception or two "effective" forms of non-hormonal contraception by the patient and/or partner. exclusion criteria: * active infection * presence of known metastases (stage iv disease) * pregnant or lactating women * prior chemotherapy or radiation therapy for the primary breast cancer * concomitant malignancies or previous malignancies within the last 5 years except adequately treated basal or squamous cell carcinoma of the skin or carcinoma in situ of the cervix. * history of significant cardiac disease, cardiac risk factors or uncontrolled arrhythmias * current severe, uncontrolled systemic disease (e.g., clinically significant cardiovascular, pulmonary or metabolic disease including diabetes, wound healing disorders, ulcers or bone fractures) * major surgical procedure or significant traumatic injury within 28 days prior to study treatment start or anticipated need for major surgery during the course of study treatment * current known infection with human immunodeficiency virus (hiv), hepatitis b virus (hbv) or hepatitis c virus (hcv) * receipt of intravenous antibiotics for infection within 14 days prior to receiving study treatment * current chronic daily treatment with corticosteroids (dose \>10 mg/day methylprednisolone equivalent) except inhaled steroids * known hypersensitivity to any of the study drugs * assessment by the investigator to be unable or unwilling to comply with the requirements of the protocol
reconstruction of the anterolateral ligament (all) with revision anterior cruciate ligament (acl) surgery

Conditions: Rupture of Anterior Cruciate Ligament; Anterolateral Ligament Reconstruction

Summary: patients with combined anterolateral ligament (all) reconstruction- anterior cruciate ligament (acl) revision will have a better rotational knee stability and therefore better patient reported outcome measure (prom) scores compared to patients, who have acl revision surgery without all reconstruction.


Eligibility criteria:
inclusion criteria: * patients with acl revision surgery indication exclusion criteria: * patients with difficulties of understanding danish

Keywords: laxity knee rupture all
glivec in pediatric chronic myeloid leukemia (cml)

Conditions: Chronic Myeloid Leukemia

Summary: it is a phase 4 study, not randomised and multicentric. within 2 months after the diagnosis, the patients daily receive imatinib by oral way during at least 1 year (260mg/m² once a day), i.e. until the cytogenetic analysis. beyond 1 year of treatment, if a haematological relapse or a loss of the cytogenetic response is observed, the nature of the treatment suggested to the patient is left with the appreciation of the investigator. later on, discontinuation of imatinib is discussed if a molecular remission (negative rt-pcr) is obtained and maintained for at least 2 years.


Eligibility criteria:
inclusion criteria: * old \< 18 years, male or female. * chronic myeloid leukaemia confirmed on the cytogenetic level by the presence of the translocation t(9; 22) (q34; q11) or by the presence of transcript bcr-abl in the event of absence of description of the translocation t(9; 22) (q34; q11). * chronic phase of a chronic myeloid leukaemia * absence of extra-medullary disease (except for a hepatomegaly and/or of a splenomegaly). * absence of any former treatment of chronic myeloid leukaemia except for hydroxyurea. * stop of hydroxyurea at least week before the beginning of the imatinib mesylate. * diagnosis of chronic myeloid leukaemia in chronic phase recent (less than 2 months). * score of lansky ≥ 60. * effective contraception among patients in age to procreate. * written voluntary informed consent of the two parents or the legal guardian. exclusion criteria: * patients with grade 3 / 4 cardiac disease. * pathology cardiac, pulmonary, hepatic, renal or neurological of grade \> 2 (who). * participation in a clinical trial in the 28 days preceding the beginning by the treatment. * impossible follow-up during at least 2 years, patient not compliant. * expectant mother or nursing.
effect of low dose metronomic chemotherapy in metastatic breast cancer

Conditions: Breast Cancer Metastatic; Chemotherapy Effect

Summary: low dose metronomic chemotherapy (ldmc) in patients with metastatic breast cancer (mbc) is used as a palliative regiment with the aim to prolong and improve quality of life. the effect of ldmc is not fully elucidated. the aim is to evaluate the effect of ldmc with capecitabine and cyclophosphamide (cx) and to discover new potential predictive markers and potential markers for monitoring treatment effect.


Eligibility criteria:
inclusion criteria: * written and informed consent * breast cancer confirmed by histology * recurrence (local or distant) not possible to cure * measurable or evaluable disease * life expectancy of more than tree months * ecog (eastern cooperative oncology group) performance 0-2 * no or any lines of previous therapies for recurrent disease. * adequate contraception for patients of child bearing age. exclusion criteria: * clinically significant cardiovascular disease * non healing wound, active peptic ulcer or bone fracture * evidence of any other disease that puts the patient at high risk for treatment-related complications